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Abstract
 
Recent clinical evidence demonstrated the importance of tumor necrosis factor (TNF) in the de-
velopment of Crohn’s disease. A mouse model for this pathology has previously been established
 
by engineering defects in the translational control of TNF mRNA (
 
Tnf
 
 
 
ARE 
 
mouse). Here, we
show that development of intestinal pathology in this model depends on Th1-like cytokines such
 
as interleukin 12 and interferon 
 
  
 
and requires the function of CD8
 
  
 
T lymphocytes. Tissue-spe-
cific activation of the mutant TNF allele by Cre/loxP-mediated recombination indicated that ei-
ther myeloid- or T cell–derived TNF can exhibit full pathogenic capacity. Moreover, reciprocal
bone marrow transplantation experiments using TNF receptor–deficient mice revealed that
TNF signals are equally pathogenic when directed independently to either bone marrow–
derived or tissue stroma cell targets. Interestingly, TNF-mediated intestinal pathology was exac-
erbated in the absence of MAPKAP kinase 2, yet strongly attenuated in a Cot/Tpl2 or JNK2 ki-
nase–deficient genetic background. Our data establish the existence of redundant cellular
pathways operating downstream of TNF in inflammatory bowel disease, and demonstrate the
therapeutic potential of selective kinase blockade in TNF-mediated intestinal pathology.
Key words: MAPK/SAPK • targeted mutants • CD8
 
  
 
lymphocytes • apoptosis • intestine
 
Introduction
 
The correlation between aberrant cytokine activity and in-
flammatory bowel disease (IBD)
 
* 
 
has been exemplified in
several animal models for this disease via the use of specific
neutralizing antibodies or cytokine gene knockouts (1). In
the majority of IBD models, TNF appears as a common
pathogenic denominator despite the variability of the insti-
gating stimuli or genetic defects leading to the develop-
ment of the disease (2–7). Recent clinical trials showed that
anti-TNF antibodies provide marked clinical benefits in
human Crohn’s disease patients (8). However, despite such
strong indications for a pathogenic relevance of TNF in
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*
 
Abbreviations used in this paper:
 
 ARE, AU-rich element; hpf, high power
fields; IBD, inflammatory bowel disease; LPMC, lamina propria mononu-
clear cell; MK2, MAPKAP kinase 2; ML, mononuclear leukocytes; NF,
nuclear factor; NO, nitric oxide; PMN, polymorphonuclear; TUNEL,
terminal deoxynucleotidyl transferase–mediated, dUTP nick end labeling. 
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IBD, the specific molecular and cellular mechanisms driv-
ing TNF-dependent disease remain poorly defined.
The activities of TNF in oligo-cellular systems and in
modeled immunological responses are now well under-
stood and the signals transduced by the two TNF receptors
(TNFRI and TNFRII) have been sufficiently detailed (9).
Current knowledge indicates that this molecule exhibits
multiple in vivo activities. It might be predicted that TNF
disturbs innate and adaptive immunoregulatory interplays
in the intestine to alleviate the state of tolerance and lead to
inappropriate responses to both nominal bacterial antigens
and to self (10). The potent innate inflammatory activities
of TNF appear central to disease induction and progres-
sion, particularly when sustained TNF overproduction is
provoked. The activation of endothelial cells, induction of
chemokines, and recruitment of neutrophils in the gut mu-
cosa induced by TNF may directly affect intestinal homeo-
stasis and provoke disease (11). The capacity of monocytes/
macrophages from patients with IBD to hyper respond to
bacterial products and to secrete inflammatory mediators,
including TNF, correlates with disease progression (12), al-
though evidence for the aetiopathogenic role of this re-
sponse is currently missing. Evidence for direct effects of
TNF on tissue stroma cell types, like intestinal epithelial
cells (13), is also available and may offer alternative mecha-
nisms for pathogenic contributions. Recent evidence indi-
cated a role for proinflammatory cytokines, like IL-6 and
IL-12, in inducing resistance of pathogenic lymphocytes to
antigen-induced cell death and driving their accumulation
in the intestine (14). TNF may also promote or suppress
the adaptive immune response. Several studies suggest that
TNF/TNFRs affect T cell proliferation, activation, cyto-
toxicity, the antigen-induced cell death of cytotoxic T
cells, and the attenuation of TCR signaling (15). The ca-
pacity of TNF to modulate adaptive immune responses was
most profoundly revealed by its role in suppressing organ-
specific or systemic autoimmune disease (15, 16). There-
fore, it is probable that TNF supports pathogenesis of IBD
at multiple levels by not only targeting innate compart-
ments or nonimmune cell types but also by modulating the
adaptive immune response. The specific contribution of
such mechanisms in the development of TNF-mediated
IBD awaits detailed investigation.
Several existing animal models of mucosal inflammation
have indicated the potential key role of an excessive Th1 cy-
tokine response and of CD4
 
  
 
effector T cells in the pathol-
ogy of IBD (1). Amongst Th1-driven cytokine responses,
those dependent on TNF have lately received much atten-
tion due to the success of anti-TNF treatments of IBD in
humans. The recent generation of a mouse developing
Crohn’s-like IBD due to an induced intrinsic defect in the
posttranscriptional regulation of TNF mRNA (
 
Tnf
 
 
 
ARE
 
mouse) offered a unique animal model for the detailed study
of TNF-driven disease mechanisms (5). In this study we
aimed to establish cellular and molecular hierarchies operat-
ing during pathology in the 
 
Tnf
 
 
 
ARE 
 
mouse with the ulti-
mate goal to uncover disease mechanisms and indicate novel
targets for therapy. We demonstrate that TNF initiates dif-
 
ferent and redundant cellular cascades that contribute to
IBD development. Interestingly, the pathogenic capacity of
these redundant cascades relies exclusively on the generation
by TNF of an IL-12– and IFN-
 
 
 
–driven Th1-like response
and on the activation of a pathogenic CD8
 
  
 
T cell compart-
ment, the latter being an important feature of human
Crohn’s IBD represented uniquely in the 
 
Tnf
 
 
 
ARE 
 
mouse
model. Analysis of the potential pathogenic significance of
effector kinase signals operating downstream of TNF in the
 
Tnf
 
 
 
ARE 
 
model identified Cot/Tpl2 and JNK2 kinases as
dominant players in the pathogenesis of IBD and revealed an
antiinflammatory role played by MAPKAP kinase 2 (MK2).
 
Materials and Methods
 
Mice.
 
The generation of 
 
Tnf
 
 
 
ARE
 
, 
 
Tnf
 
 
 
AREneo
 
, 
 
Tnf
 
 
 
ARE
 
TnfRI
 
 
 
/
 
  
 
(5), 
 
MAPKAP K-2
 
 (17), 
 
Jnk2
 
 (18), 
 
Tpl-
 
2 (19), and
 
LysM Cre
 
 (20) mice has been previously described. 
 
TnfRI- 
 
(21),
 
CD4-
 
 (22), 
 
 
 
2M-
 
 (23), 
 
IL-12p40-
 
 (24), 
 
IFN
 
 
 
-
 
 
 
(25), 
 
 
 
MT-
 
 (26),
and 
 
TcR
 
 
 
- (27) deficient mice were obtained from The Jackson
Laboratory. Double 
 
TnfRI-
 
 and 
 
TnfRII
 
-deficient mice (
 
TnfRI/
RII
 
 
 
/
 
 
 
), as well as triple compound mutants 
 
Tnf
 
 
 
ARE 
 
TnfRI
 
 
 
/
 
 
 
TnfRII
 
 
 
/
 
  
 
(Tnf
 
 
 
ARE 
 
TnfRI/
 
II
 
 
 
/
 
 
 
), were generated by breeding
 
TnfRI
 
 
 
/
 
  
 
and 
 
Tnf
 
 
 
ARE 
 
TnfRI
 
 
 
/
 
  
 
into a 
 
TnfRII
 
-deficient back-
ground (28). The transgenic 
 
Lck-
 
Cre (29) mice were provided by
J.D. Marth, University of California, San Diego, San Diego, CA.
All mice were bred and maintained on a mixed C57BL/
6J
 
 
 
129S6 genetic background in the animal facilities of the Bio-
medical Sciences Research Center “Alexander Fleming” under
specific pathogen-free conditions.
 
Histological and Immunocytochemical Assessment of Inflammation.
 
Paraffin-embedded intestinal tissue samples were sectioned and
stained with hematoxylin and eosin and two 1.5-cm sections of il-
eum were histologically evaluated in a blinded fashion. Acute and
chronic inflammation were assessed separately in a minimum of
eight high power fields (hpf) using a semiquantitative (0–4
 
 
 
) scor-
ing system as follows: acute inflammatory score, 0 
 
  
 
0–1 polymor-
phonuclear (PMN) cells per hpf (PMN/hpf); 1 
 
  
 
2–10 PMN/hpf
within mucosa; 2 
 
  
 
11–20 PMN/hpf within mucosa; 3 
 
  
 
21–30
PMN/hpf within mucosa or 11–20 PMN/hpf with extension be-
low muscularis mucosae; and 4 
 
   
 
30 PMN/hpf within mucosa
or 
 
 
 
20 PMN/hpf with extension below muscularis mucosae.
Chronic inflammatory score, 0 
 
  
 
0–10 mononuclear leukocytes
(ML) per hpf (ML/hpf) within mucosa; 1 
 
  
 
11–20 ML/hpf within
mucosa; 2 
 
  
 
21–30 ML/hpf within mucosa or 11–20 ML/hpf
with extension below muscularis mucosae; 3 
 
  
 
31–40 ML/hpf
within mucosa or 21–30 ML/hpf with extension below muscularis
mucosa or follicular hyperplasia; and 4 
 
   
 
40 ML/hpf within mu-
cosa or 
 
 
 
30 ML/hpf with extension below muscularis mucosae or
follicular hyperplasia. Total disease score per mouse was calculated
by the summation of the acute inflammatory or chronic inflamma-
tory scores for each mouse (data represented as mean 
 
  
 
SD). For
immunocytochemistry, frozen cryostat sections were fixed in ace-
tone (BDH) and after rehydration were stained with anti–CD4-
FITC, anti–CD8-PE, anti–CD11b FITC, anti–B220-PE, and
anti–Gr-1 biotin followed by streptavidin-PE (BD Biosciences)
and then analyzed via immunofluorescent microscopy.
 
In Situ Detection of Lamina Propria Mononuclear Cell (LPMC) Ap-
optosis via Terminal Deoxynucleotidyl Transferase–mediated, dUTP Nick
End Labeling (TUNEL) Assay.
 
TUNEL assays were performed
on paraffin-embedded ileal sections from 3-mo-old mice (
 
n
 
 
 
  
 
3
mice/group). After deparaffinization and rehydration, sections 
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were treated with pepsin-HCL (Sigma-Aldrich) for 15 min.
Next, terminal deoxynucleotidyl transferase–mediated incorpo-
ration of digoxigenin-labeled dUTP (Roche) was performed by
applying the reaction mixture in tailing buffer (Roche) for 1 hr at
60
 
 
 
C. Apoptotic cells were detected using alkaline phosphatase–
conjugated sheep anti–digoxigenin Fab fragments (Roche) and the
Vector ABC and Fast Blue kits (Vector Laboratories). Sections
were counterstained with nuclear red (Vector Laboratories). For
quantitation of LPMCs, four photomicrographs/section were ac-
quired at hpf 
 
 
 
200 and were analyzed with the Corel Photo-
paint (Corel) software using a 4 
 
  
 
5 grid. The area between the
epithelial cells and the muscularis (as indicated by the nuclear
red counter stain) was scanned for the total number of LPMCs
present and the number of apoptotic cells per hpf were quanti-
fied. The apoptotic index was calculated from the corresponding
values as the percentage of apoptotic cells per total number of
LPMCs.
 
Immunostaining and Flow Cytometry.
 
Spleens were collected
from 4- or 8-wk-old normal and mutant mice. After erythrocyte
lysis, 10
 
6 
 
single cell suspensions were stained at 4
 
 
 
C for 30 min
with the corresponding antibodies in PBA (PBS, 3% FBS, 0.1%
NaN
 
2
 
) and analyzed on a Coulter EPICS Elite flow cytometer.
Anti–CD4-FITC, anti-CD4 CyChrome, anti–CD8-PE, anti-
CD8 CyChrome, anti–CD25-PE, anti-CD69 biotin, anti–
CD11b FITC, and anti-CD45RB biotin followed by streptavi-
din-PE (BD Biosciences) were used.
 
Cell Isolation and Culture.
 
All cultures were grown and main-
tained at 37
 
 
 
C, 5% CO
 
2
 
. Total exudate peritoneal macrophages
were isolated by peritoneal lavage from 
 
 
 
10-wk-old mice 3 d af-
ter a single peritoneal injection of aged 4% thioglycollate broth (1
ml; Difco Laboratories). Splenocytes were collected from 1-mo-
old nondiseased 
 
Tnf
 
 
 
ARE/
 
  
 
and littermate controls. After erythro-
cyte lysis, spleen cells were used as they were or enriched for T
cells after nylon wool treatment, or enriched for B cells after anti-
CD4 and anti-CD8 and complement lysis of T cells. For cyto-
kine determination assays, cells were plated at 5 
 
  
 
10
 
5 
 
cells (for
macrophages) or 5 
 
  
 
10
 
6 
 
cells (for lymphocytes) onto 24-well
plates and stimulated with LPS (Sigma-Aldrich), anti-CD3 (BD
Biosciences), or pockweed mitogen (Sigma-Aldrich). After a 12–
24-h incubation, supernatants were collected and analyzed using
specific ELISAs.
 
Cytokine and Nitric Oxide (NO) Determination Assays.
 
TNF
and IL-6 levels in culture supernatants were determined using a
sandwich TNF (5) and mIL-6 (Endogen) ELISAs. To evaluate
NO, NO
 
3
 
  and NO2
  were measured from cell culture superna-
tants using a standard Griess assay.
Mixed Lymphocyte Reactions and Assessment of CTL Activity.
The cytotoxic activity of spleen cells to lyse epithelial cells was
evaluated using the syngeneic (H-2b) colonic epithelial cell line
CMT-93 as target. CMT-93 cells were first pulsed with [3H]thy-
midine for 24 h in RPMI   5% FBS medium and then treated
with 2  g/ml mitomycin C (Sigma-Aldrich) for 30 min to arrest
cell growth. After washes, cells were plated onto 96-well tissue
culture plates in triplicates (104 per well) and incubated with ef-
fector cells at different E/T ratios (1:1 to 100:1) in 0.2 ml com-
plete medium. After incubation for 12 h, the plates were washed
three times with PBS to remove nonadherent cells. The remain-
ing radioactivity present in target cells was measured using a
gamma counter.
Bone Marrow Transplantation. Bone marrow from 8-wk-old
mutant and wild-type (B6,129) female mice was obtained from
femurs and tibia. 107 bone marrow cells in 200  ls were injected
intravenously into lethally irradiated (1,000 rads) female (B6,129)
mice. Mice were maintained in isolated/specific pathogen-free
conditions and kept on an antibiotic regime for 2 wk. Reconsti-
tution was assessed via specific staining for CD4/CD8, B220,
CD11b, and Gr-1 antigens via FACS® analysis of heparinized
blood samples. Mouse body weight was assessed weekly. At the
end of the study, spleen cells were isolated for TNF measure-
ments and DNA detection of the  ARE mutation using South-
ern analysis. For the engraftment of Tnf /  bone marrow into
Tnf ARE/  hosts, 2-wk-old Tnf ARE/  female mice were treated
weekly with 600  g anti-TNF antibody (TN3. 9-12. 1;
Celltech) until the age of 7.5 wk old to prevent IBD develop-
ment. Mice were irradiated and reconstituted with Tnf /  bone
marrow as described above and were kept with decreasing doses
of antibody until reconstituting hemopoietic cells appeared in pe-
ripheral blood (3 wk). Mice were then left untreated for 9 more
wk to assess for the development of the disease relative to nonir-
radiated Tnf ARE/  mice that followed the same antibody treat-
ment regime.
Results
TNF-driven IBD Requires the Effector Function of Non-
  TCR CD8  T Cells and Is Dependent on IL-12 and
IFN- . We have previously reported that a targeted
mouse mutant bearing a deletion in the 3  AU-rich ele-
ments (AREs) of TNF mRNA (Tnf ARE mice) overpro-
duces TNF and develops a unique IBD phenotype with re-
markable histopathological similarity to Crohn’s disease (5).
In this model, IBD develops between 4–8 wk of age (Fig. 1
A; reference 5) and is restricted to the terminal ileum (Fig.
1 B) and occasionally to the proximal colon (5). Its basic
histopathological characteristics include villus blunting and
submucosal inflammation with prevailing PMN/macro-
phage and lymphocytic exudates, proceeding to patchy trans-
mural inflammation and the appearance of lymphoid aggre-
gates and rudimentary granulomata (Fig. 1 B; reference 5).
We have previously demonstrated that intestinal pathology
in this model is dependent on the presence of mature lym-
phocytes (e.g., in Tnf ARE Rag-1 /  mice; Table I and ref-
erence 5), which suggests that TNF deregulation perturbs
adaptive immune responses to support the development of
IBD. During the course of our analysis we noted that the
development of the Tnf ARE IBD phenotype correlated
with the development of mild splenomegaly, which follows
the course of the disease (Fig. 1, A and C) and becomes sig-
nificant at 4 mo of age. Flow immunocytometric analyses
indicated that the increase in total splenocyte counts noted
past the age of 2 mo correlated with significant increases in
CD11b  myeloid cells and CD8  T lymphocytes (Fig. 1
C). Notably, expression of the CD44, CD69, and CD25
markers was enhanced in Tnf ARE/  CD8  lymphocytes,
indicating that these cells are in an activated/memory state
(Fig. 1, D–F). In sharp contrast, the corresponding CD4  T
cell populations appeared similar to the control groups up
to 4 mo of age (Fig. 1, D–F), although a slight increase in
corresponding memory compartments was detected past
the age of 7 mo (not depicted).
Examination of the CTL effector activity in Tnf ARE/ 
cultures from inflamed animals by means of measuring the1566 Molecular and Cellular Pathways in TNF-mediated IBD
ability of Tnf ARE/  splenocytes to lyse syngeneic (H-2b)
CMT-93 cell targets in vitro, revealed that Tnf ARE spleno-
cytes exhibited a high degree of target cell lysis at E/T ra-
tios as low as 10 (Fig. 2 B). Interestingly, the observed tar-
get cytolysis was not mediated by TNF because it could
not be blocked by anti-TNF antibody treatment (Fig. 2 B).
When examined in allogeneic (BALB/c, H-2d) MLRs,
Tnf ARE/  splenocytes (H-2b) from 4-wk-old, disease-free
animals showed significantly enhanced proliferation com-
pared to Tnf /  controls, even at low doses of alloantigen
(not depicted). The apparent hyperproliferation of Tnf ARE/ 
splenocytes in the MLRs correlated with a stimulus-depen-
dent twofold increase in the number of activated CD8  but
not CD4  T cells (not depicted). Taken together, these
data indicate that chronic overproduction of TNF in Tnf ARE
mice results in the selective accumulation of activated/
memory CD8  T cell subsets. This accumulation correlates
with an increased reactivity to allogeneic and syngeneic tar-
gets, and may therefore bear direct pathogenic significance
in the development of IBD.
To validate the potential involvement of specific lym-
phocyte subsets in the pathogenesis of TNF-driven IBD,
we generated Tnf ARE mice congenitally lacking CD4  or
CD8  T cells by crossing into CD4 or  2-microglobulin–
deficient backgrounds, respectively (22, 23). Interestingly,
elimination of CD4  T cells resulted in disease exacerba-
tion associated with high incidences of mortality in Tnf ARE/ 
CD4 /  groups by the age of 2–3 mo (Table I and unpub-
lished data). In striking contrast, elimination of MHC-I/
CD8  T cell responses in Tnf ARE/  mice resulted in the
delayed development and significant attenuation of IBD
(Table I). Interestingly, Tnf ARE/   MT /  and Tnf ARE/ 
TcR  /  mice, which are devoid of B cells and   TcR T
cells, respectively (26, 27), developed IBD with similar
Figure 1. Development of TNF-mediated IBD
correlates with the systemic activation of CD8  T cell
effectors. (A) Graphical representation of acute (AI)
and chronic (CI) inflammatory indices calculated from
the histopathological evaluation of Tnf ARE/  ( ) and
Tnf /  control ( ) ileal sections, indicating the course
of ileitis development. (B) Representative histological
analysis for the detection of total exudates as well as
immunocytochemical analysis for the detection of
CD11b /Gr-1  (myeloid) and CD4 /CD8  (T lym-
phocytic) cells in the ileal sections of 3-mo-old Tnf / 
and Tnf ARE/  mice. H/E, hematoxylin and eosin stain-
ing.  100 and  200, respectively. (C) Age-dependent
variation of the splenocyte cellular content in lympho-
cytes, myeloid, and dendritic cells in Tnf ARE/  ( ) and
Tnf /  control ( ) after the flow cytometric detection
of the corresponding populations. Data represents ab-
solute values (  SD) collected from 5–15 mice per
group. *, values with significant statistical differences
(P   0.05). (D) Representative density and histogram
plots after the flow cytometric detection of CD4 
and CD8  T cell populations (right) in the spleens of
4-mo-old Tnf /  and Tnf ARE/  mice and detection of
memory marker CD44 on CD4 /CD8  gated lym-
phocytes. (E) Representative density plots for the acti-
vation markers CD69 and CD25 on CD4 /CD8 
gated Tnf ARE/  and control splenocytes. (F) Graphical
representation of estimated percentages for CD44,
CD69, and CD25 on CD4 /CD8  gated Tnf ARE/ 
and control splenocytes. Histogram values derived
from percentages of cells in the corresponding quad-
rants. Data (values   SD) collected from 15 mice per
group at the age of 4 mo. *, values with significant sta-
tistical differences (P   0.05).1567 Kontoyiannis et al.
severity to the control groups, indicating that these lym-
phocyte subsets are not actively involved in the develop-
ment of the disease (Table I). Finally, the introduction of
the Tnf ARE allele into IL-12 p40 (24) or IFN - (25) defi-
cient backgrounds attenuated the development of intesti-
nal inflammation, indicating the importance of Th-1–like
cytokines in TNF-induced IBD. In contrast, disease in-
duction and progression remained unaltered in Tnf ARE/ 
IL-4 /  mice (30 and unpublished data). Collectively,
these data demonstrate that chronic TNF over-production
in Tnf ARE mice promotes a pathogenic Th1-like cytokine
response, which, together with non-  TCR, CD8  ef-
fector T cells play an essential role in the development of
chronic progressive inflammatory pathology in the intes-
tine.
Redundancy in the Cellular Sources of TNF-driving IBD:
Myeloid Cells or T Lymphocytes Are Sufficient in Providing
Pathogenic TNF Loads. To identify the cellular source(s)
of pathogenic TNF in our model, we set up a system of
tissue-specific activation of the Tnf ARE allele. To this end,
we used a targeted mutant mouse strain, which contains a
“hypomorphic” Tnf AREneo allele generated by the intro-
duction of a neomycin acetyltransferase gene (neor gene)
flanked by loxP sequences next to the  ARE mutation
(Fig. 3 A; reference 5). Mice of the Tnf AREneo genotype
show a low to normal range of myeloid- and lymphoid-
Table I. Effect of Selective Deletion of Adaptive Mediators on the Incidence and Severity of Tnf ARE Crohn’s Ileitis
Mouse genotype
Disease Score Distributiona
Ileum
Mean disease 
scorea
0–0.5 0.5–1 1–2 2–3
Tnf ARE/  Rag-1    n   10b AI 1 2 5 2 1.67   0.68
CI 1 2 6 1 1.60   0.52
Tnf ARE/  Rag-1    n   10b AI 6 4 0.70   0.25d
CI 7 3 0.65   0.24d
Tnf ARE/   MT    n   9b AI 5 1 3 1.02   0.90
CI 2 4 2 1 1.22   0.66
Tnf ARE/   MT    n   10b AI 5 1 2 2 1.12   0.85
CI 1 5 2 2 1.45   0.79
Tnf ARE/  CD4    n   8b AI 1 2 1 4 2.00   0.83
CI 1 2 1 4 2.06   1.11
Tnf ARE/  CD4    n   10b AI 1 9 3.00   0.52d
CI 1 9 2.80   0.34d
Tnf ARE/   2M    n   7c AI 1 2 2 2 1.87   0.46
CI 3 2 2 2.00   0.89
Tnf ARE/   2M    n   9c AI 3 4 2 0.74   0.55d
CI 3 4 2 0.77   0.46d
Tnf ARE/  TcR     n   7c AI 1 2 2 2 1.64   1.02
CI 1 5 1 1.82   0.83
Tnf ARE/  TcR     n   11b AI 1 2 3 5 1.84   0.95
CI 1 2 2 6 1.95   0.82
Tnf ARE/  il-12    n   6c AI 1 3 2 1.95   0.55
CI 5 1 2.08   0.49
Tnf ARE/  il-12    n   10c AI 5 5 0.67   0.33d
CI 1 8 1 0.90   0.37d
Tnf ARE/  Ifn     n   6c AI 1 5 2.66   0.40
CI 1 1 4 2.75   0.41
Tnf ARE/  Ifn     n   7c AI 4 2 1 0.64   0.74d
CI 3 2 2 1.00   0.57d
AI, acute inflammatory index; CI, chronic inflammatory index.
aMean severity of inflammatory lesions (refer to Materials and Methods for a description of histologic analysis).
Mice and littermate controls at the age of b2–3 and c3–4 mo.
dA significant difference to corresponding control group score (assessed by using unpaired Student’s t test).1568 Molecular and Cellular Pathways in TNF-mediated IBD
specific TNF production compared with Tnf  mice and
do not develop any signs of intestinal pathology even at
homozygosity (Fig. 3, C and D). After germ line or tissue-
specific expression of Cre recombinase, the loxP se-
quences allow for the complete or tissue-specific removal
of the “floxed” neor gene and the respective activation of
the Tnf ARE allele (Fig. 3, A–C).
To restrict the production of TNF by the Tnf ARE allele
in cells of the myeloid lineage, we crossed Tnf AREneo mice
to mice expressing Cre under the control of the endoge-
nous lysozyme M promoter (LysM-Cre mice; reference
20). Cre-specific recombination and TNF overproduction
was confirmed to be restricted to the myeloid cell compart-
ment. (Fig. 3, B and C). Both LysM-Cre/Tnf AREneo/  and
LysM-Cre/Tnf AREneo/ AREneo mice appeared grossly normal
until the age of 4 mo. Past this age, both groups developed
symptoms of weight loss, which were more severe in the
LysM-Cre/Tnf AREneo/ AREneo mice (unpublished data). His-
tological evaluation indicated the development of Crohn’s-
like IBD in both heterozygous and homozygous LysMCre/
Tnf AREneo mice (Fig. 3, E and F).
To examine whether TNF hyperproduction by T lym-
phocytes suffices to elicit IBD we also generated Tnf AREneo
mice carrying the Cre transgene under the control of the
proximal lck promoter (29). In this case, Cre-specific re-
combination and TNF overproduction was found to be re-
stricted to the lymphoid compartment. (Fig. 3, B and C).
The lck-Cre/Tnf AREneo/  mice did not develop signs of in-
testinal pathology (not depicted). However, lck-Cre/
Tnf AREneo/ AREneo mice developed IBD past 5 mo of age, al-
though with reduced severity relative to LysM-Cre/
Tnf AREneo/ AREneo and Tnf ARE/  mice (Fig. 3 G). In contrast
to myeloid and T cell compartments, TNF overproduction
by the B cell lineage by means of Cre-mediated activation
of the Tnf AREneo allele in CD19  B cells (31), did not result in
Figure 2. CTL activity of Tnf ARE splenocytes in response to syngeneic
stimulation. CTL assay on the syngeneic epithelial cell line CMT-93. Mi-
tomycin C–treated, 3[H]thymidine-pulsed CMT-93 target (T) cells were
cocultured with increasing numbers of wild-type (left) and Tnf ARE/ 
effector (right) in the presence or absence of anti-CD3 (2C11) or anti-
TNF antibody (TN3). 3[H] label loss indicates target cell lysis.
Figure 3. Myeloid- and lym-
phoid-specific deregulation of
TNF biosynthesis. (A) Structure
of the TNF/LT   locus on
mouse chromosome 17 and the
strategy for the Cre-specific re-
moval of floxed neor allele. Filled
boxes represent exons and gray
shaded boxes represent untrans-
lated regions. Filled arrowheads
indicate the position of the loxP
sequences. The positions of the
TNF AU-rich element (ARE)
and the floxed neo marker are
indicated. The location of the 3 
0.4-Kb BglII probe is also indi-
cated. Restriction enzyme sites
are Bg:BglII, K:KpnI, N:NotI,
and S:SacI. (B) Southern blot
analysis of BglII-digested DNA
from tail, peritoneal cavity cells
(PEC), total exudate peritoneal
macrophages, and T and B lym-
phocytes from LysM-Cre or lck-Cre
Tnf AREneo  mice. Detected with
the 3   probe are the neo  (1.6
Kb),  neo- (0.5 Kb), and wild-
type (0.4 Kb) fragments. (C)
TNF protein production as de-
termined by ELISA in culture supernatants from peritoneal macrophages (left) or splenic T cells (right) isolated from individual LysM-Cre (LysC) or
lck-Cre (lckC) Tnf AREneo ( n) mice and stimulated with LPS or anti-CD3, respectively. Data shown as mean ng/ml (  SD) per group. P   0.02 relative
to (*) Tnf AREneo/  or (*) Tnf AREneo/ AREneo values with n   3 mice/group. Histologic examination of ileal sections from 5-mo-old (D) Tnf AREneo/ AREneo,
(E) LysM-Cre Tnf AREneo/ , (F) LysM-Cre Tnf AREneo/ AREneo, and 7-mo-old (G) lck-Cre Tnf AREneo/ AREneo mutant mice. Paraffin sections stained with he-
matoxylin and eosin.  100.1569 Kontoyiannis et al.
the development of IBD even in CD19-Cre/Tnf AREneo/ AREneo
mice past 15 mo old (unpublished data).
To confirm the tissue origin of TNF-producing cells that
support the development of TNF-mediated IBD and to
examine whether non-bone marrow–residing cells may
also contribute pathogenic TNF loads, we performed a se-
ries of bone marrow engraftment experiments into lethally
irradiated recipients. When bone marrow from Tnf ARE/ 
mice was transplanted into lethally irradiated (B6,129)
Tnf /   mice, the majority of the recipients exhibited
weight loss 4–6 wk after transplantation (not depicted) and
fully developed IBD 10–12 wk after transplantation. The
disease borne all the pathological hallmarks of the donor’s
disease (Table II and Fig. 4 B), including the accumulation
of activated CD8  T cells (not depicted). In contrast, none
of the Tnf /  recipients of Tnf /  bone marrow developed
signs of intestinal pathology (Table II and Fig. 4 A). To ex-
amine whether radio-resistant Tnf ARE stromal cells suffice
to induce IBD, we transplanted Tnf /  bone marrow into
irradiated Tnf ARE/  mice. In this case, and to prohibit the
development of IBD in the host before transplantation,
Tnf ARE/  mice were treated with anti-TNF antibody be-
fore irradiation and were kept without antibody adminis-
tration after reconstitution (refer to Materials and Meth-
ods). Nonirradiated control groups treated with anti-TNF
antibody until the age of reconstitution of the test groups
developed full IBD 9 wk after the removal of the antibody
(Fig. 4 C). In sharp contrast and at this same age, irradiated
Tnf ARE/  mice reconstituted with Tnf /  bone marrow
showed mild signs of villus blunting but did not develop
intestinal inflammation (Fig. 4 D). Taken together, these
findings indicate that bone marrow–derived TNF produc-
ers such as myeloid cells and/or T lymphocytes, but not tis-
sue stroma cells, constitute cellular sources of TNF with
full independent capacity for inducing IBD.
Redundancy in the Cellular Targets of TNF Function in IBD:
Bone Marrow– or Tissue Stroma–residing Cell Targets Are
Equally Responsive to the Pathogenic Effects of TNF. To
gain insight on specific cellular targets of TNF function in
the Tnf ARE model, we performed a series of additional re-
ciprocal bone marrow transplantation experiments between
wild-type,  Tnf ARE, and TNF receptor–deficient mice.
Transfer of Tnf ARE/  TnfRI /  or Tnf ARE/  TnfRI,II / 
bone marrow into wild-type irradiated recipients readily
resulted in an IBD phenotype similar to the Tnf ARE recon-
stituted mice, as indicated by the histopathological findings
12 wk after transfer (Table II and Fig. 4 E), suggesting that
radiation-resistant, tissue stroma–residing cells are sufficient
TNF targets for the induction of IBD. Remarkably, a simi-
lar disease profile 12 wk after engraftment was obtained in
the reciprocal experiment, i.e., the transfer of Tnf ARE/ 
bone marrow into TnfRI,II /  or TnfRI /  recipients (Ta-
ble II and Fig. 4 F), indicating that radiation-sensitive, bone
marrow–derived cells are equally important and sufficient
targets for pathogenic TNF.
These findings clearly indicate the existence of indepen-
dent, yet redundant, cellular pathways operating down-
stream of TNF in the pathogenesis of IBD.
Disease-promoting Signals via the tpl2 and JNK-2 Kinases
and Opposing Signals by MK2 in IBD. The redundancy of
cellular interactions promoted by TNF in modeled IBD in-
dicated the difficulty in targeting such mechanisms to in-
hibit the disease. Therefore, we aimed to genetically iden-
tify intracellular signaling pathways that could affect a
pleiotropy of cellular responses to provide a therapeutic
Table II. IBD Development after Tnf ARE Bone Marrow 
Reconstitution of Lethally Irradiated Recipients
Donor genotypea
Recipient
genotypeb
IBD
developmentd
Tnf    Tnf    0/10
Tnf ARE/  Tnf    9/11
Tnf    Tnf ARE/ c 0/5
Tnf ARE/ ARE TnfRI    Tnf    3/3
Tnf ARE/ ARE TnfRI/RII    Tnf    4/4
Tnf ARE/  TnfRI    3/3
Tnf ARE/  TnfR/,II    3/3
Bone marrow isolated from a2-mo-old female B6,129 mice was en-
grafted onto b6–8-wk-old syngeneic, lethally irradiated female mice.
cTransfers onto Tnf ARE/  recipients were performed on anti-TNF–
treated animals until the day of transfer to inhibit prior disease develop-
ment.
dAssessment based on histopathological evaluation of intestinal samples
12 wk after transfer.
Figure 4. TNF individually targets hemopoietic and stromal compo-
nents to induce IBD. Representative photomicrographs of ileal sections
from bone marrow–reconstituted mice. (A) Tnf /  bone marrow into
Tnf /  recipient, (B) Tnf ARE/  bone marrow into Tnf /  recipient, (C)
anti-TNF–treated control, (D) Tnf /  bone marrow into Tnf  ARE/  re-
cipient (refer to Materials and Methods and text for details), (E) Tnf / 
TNFRI/II /  bone marrow into Tnf /  recipient, and (F) Tnf ARE/  bone
marrow into TNFRI/II /  recipient. Paraffin sections stained with hema-
toxylin and eosin.  100.1570 Molecular and Cellular Pathways in TNF-mediated IBD
outcome. Mitogen- and stress-activated protein kinase
MAPK/SAPK-mediated intracellular signals have been nu-
merously associated with immune pathologies (32). How-
ever, in most cases, blockade of these pathways lead to the
biosynthetic blockade of several proinflammatory media-
tors including TNF, masking the role of these molecules in
complex downstream cellular responses. We have previ-
ously shown that the SAPKs p38 and JNK, and the MKKK
Cot/Tpl2 kinase, target the 3  ARE sequences of TNF
mRNA to modulate the biosynthesis of TNF (5, 7, 19, 33).
Consequently, TNF production by the mutated Tnf ARE
gene in the mouse should not be affected by the presence
or absence of these specific kinases. This finding suggested
that ablation of these kinases in Tnf ARE mice may provide
clues on their role in the effector functions of TNF inde-
pendent of their effects on TNF biosynthesis. Based on
these considerations, we generated Tnf ARE mice deficient
in the p38-activated MK2 (17, 33), the JNK2 kinase (18,
34), or the Tpl2 kinase (19). The absence of MK2, Tpl2,
and JNK2 kinases did not reduce the production of TNF
by LPS-stimulated Tnf ARE macrophages. In addition, the
production of two other proinflammatory mediators, IL-6
and NO, by TNF and LPS-stimulated Tnf ARE macro-
phages was not compromised by the absence of MK2, JNK2,
or Tpl2, whereas in contrast, in the latter two groups it was
significantly higher (not depicted). This data indicates that
the proinflammatory impetus can be maintained in Tnf ARE
mice in the absence of these kinase signals.
Contrary to its presumed requirement for the activation
of proinflammatory programs, the absence of the MK2 sig-
naling pathway resulted in the profound exacerbation of the
Tnf ARE phenotype and was associated with high incidences
of mortality from the age of 8 wk onwards (Fig. 5 A and
unpublished data). IBD development in Tnf ARE/  mk2 / 
mice was associated with the early formation of multiple
granulomas and extensive lymphocytic aggregates in the
lamina propria (Fig. 5 D). In striking contrast, the absence
of the JNK2 or the Tpl2 kinases resulted in a delayed onset
and a significant attenuation in the development of IBD
(Fig. 5, A, E, and F). In both cases, chronic intestinal in-
flammation (i.e., macrophage and lymphocytic exudates)
was significantly reduced (Fig. 5 A). Flow immunocytomet-
ric analysis of splenocyte populations from the kinase-defi-
cient animals at the age of 4 mo indicated that relative to
control  Tnf ARE populations, CD4  to CD8  lymphocyte
ratios remained unaltered in MK2- and JNK2-deficient ani-
mals (not depicted) but not in Tpl2-deficient animals (Fig. 5
B). Despite the increased presence of CD11b  and Gr1 
myeloid cells, indicating a persistent innate immune activa-
tion (not depicted), Tnf ARE/  tpl2 / –deficient splenocytes
contained a higher content of T lymphocytes than Tnf ARE/ 
controls (not depicted), but a correct CD8/CD4 ratio
(Fig. 5 B). Interestingly, this difference was attributed to a
significant increase in total CD4  counts, which primarily
possessed a CD44lo  phenotype indicating that they are
mostly accumulating in a naive state (Fig. 5 B). Most impor-
tantly, the number of CD8  CD44hi T cells was found to be
significantly reduced in Tnf ARE/  tpl2 /  splenocytes rela-
tive to Tnf ARE/  controls (Fig. 5 B), suggesting that the ab-
sence of Tpl2 affects the pathogenic lymphocytic responses.
The absence of any significant alterations amongst the
Tnf ARE/  peripheral lymphocytes in the presence or ab-
sence of MK2 and JNK2 kinases suggested that these signals
may affect events in the locality of the intestine. Recent ev-
idence indicated a strong correlation between the death of
lymphocytic (or other) infiltrates in the intestine and the
modulation of intestinal inflammation (14). Thus, we
counted the number of apoptotic cells in inflamed ileal sec-
tions from Tnf ARE/  mice in the absence of MK2 and Jnk2,
using a TUNEL Assay. To circumvent the problem of the
difference in inflammation between these groups we se-
lected ileal samples with similar inflammatory indices. More
specifically, we compared the number of apoptotic cells in
inflamed ilea from 3-mo-old Tnf ARE/  mice, 2-mo-old
Tnf ARE/  mk2 /  mice, and 7-mo-old Tnf ARE/  JNK2 / 
mice bearing comparable numbers of LPMCs (Fig. 6 A). A
high incidence of apoptotic cells was observed in the com-
partment of the LPMCs in Tnf ARE/  ilea at the age of 3 mo.
(Fig. 6, A and B). Strikingly, the number of positive apop-
Figure 5. MK2, JNK2, and Tpl2 kinase–mediated signals in the devel-
opment of TNF-mediated IBD. (A) Chronic inflammatory indices (CI)
indicating the development of intestinal inflammation based on the histo-
pathological assessment of Tnf ARE/  mice ( ) in MK2- ( ), Jnk2- ( ),
and Tpl2- ( ) deficient backgrounds. (B) Representative density and his-
togram plots indicating the percentages of CD4  and CD8  T cells as well
as their percentages of CD44  marker in Tnf ARE/  and Tnf ARE/  Tpl2 / 
splenocytes after flow immunocytometric analysis. (C–F) Representative
histology of 3-mo-old (C) Tnf ARE/  mice bred into (D) MK2-, (E) Jnk2-,
or (F) Tpl2-deficient backgrounds. All paraffin sections were stained with
hematoxylin and eosin.  100.1571 Kontoyiannis et al.
totic cells was significantly lower in Tnf ARE/  mk2 / –defi-
cient ilea suggesting a significant inhibition of cell death in
the absence of MK2 (Fig.6, A and C). In contrast, the num-
ber of apoptotic cells in Tnf ARE/  JNK2 /  ilea was dra-
matically increased relative to the lower cell numbers in the
infiltrate indicating an increased rate of apoptosis (Fig. 6, A
and D). Comparison of the apoptotic indices between
3-mo-old Tnf ARE/  ilea and 6-mo-old Tnf ARE/  Tpl2 / 
did not reveal any significant differences (not depicted).
Overall, our data suggest that Tpl2 and JNK2 kinases favor,
whereas the MK2 kinase opposes, the development of IBD.
Discussion
Regardless of the aetiopathogenic event(s) that initiate
IBD, aberrant TNF production and function appear to be
centrally involved in the pathogenesis of both the human
disease and its animal models. TNF hyperproduction in the
Tnf ARE model results from the loss of translational and sta-
bility controls on the TNF mRNA and the lack of antiin-
flammatory regulation of TNF production (5, 7, 19). From
the data presented here, it is clear that the inflammatory
impetus provided by this permutation impels multiple and
overlapping cellular cascades that can be modulated by dis-
tinct intracellular signals.
The Cellular Interactions Governing TNF-mediated IBD.
The data presented here extend earlier observations suggest-
ing a pathogenic role for TNF derived from innate effectors
in supporting intestinal inflammation (35, 36). It seems that
the intrinsic capacity of myelomonocytic cells to hyperpro-
duce TNF due to the ARE defect coupled to their exten-
sive presence in the anatomical site of the intestine, which is
rich in lumenal bacterial products, can lead to the unre-
stricted presence of numerous proinflammatory mediators
that besides TNF may include IL-1 , IL-6, and IL-12. This
pathogenic milieu can cause tissue damage, recruit inflam-
matory exudates from the periphery supporting chronic in-
testinal inflammation, and most importantly, increase anti-
gen-presenting molecules on the surfaces of hemopoietic
and stromal cells thus increasing their ability to present lu-
menal antigens and bacterial products (12). From our data it
is clear that T lymphocyte–derived TNF is also sufficient,
albeit less efficacious, to drive the pathogenic events leading
to IBD. Although currently unclear, the pathogenic differ-
ence between myeloid and T cell–derived TNF may lie on
differences in the tissue distribution of these cells, the mode
of their activation by different stimuli, the amount of TNF
they produce after stimulation, and the type of pathogenic
cascades that they are capable of inducing on target cells.
The action of TNF in IBD, as exemplified by our studies,
does not seem to be solely of an innate proinflammatory
character but may extend in the modulation of a specific
lymphocytic response. Most animal models representing a
Th1-driven mucosal inflammation seem to depend on aber-
rations either on the effector functions of CD4  T cell sub-
sets or defects in a CD4 -mediated counter response (1). In
contrast, the aberrant TNF load in our model shapes up a
hyperactive CD8  lymphocytic response, which is detect-
able in the periphery of Tnf ARE mice even before the onset
of IBD as suggested by our MLR assays. Most importantly,
our data demonstrate a dominant role for Th1-driven
CD8  T cells as IBD effectors in Tnf ARE mice. Intriguingly,
this unique property of the Tnf ARE model appears in line
with its Crohn’s-like ileal localization of mucosal inflamma-
tion, a characteristic that is different to the colonic localiza-
tion of the mucosal lesions in the CD4  T cell–dependent
models (1). Interestingly, enhanced peripheral blood T cell
cytotoxicity attributed to CD8  lymphocytes has been de-
tected in patients with Crohn’s disease (37, 38). More re-
cently, transgenic overexpression of IL-15 in the murine
small intestine led to the local activation of TNF/IFN -
producing CD8     T cells that supported the develop-
ment of small intestinal inflammation (39). CD8  T cells are
numerously represented in the intestinal mucosal, intraepi-
thelial and lamina propria, lymphocyte fractions and their
cytotoxic T cell function supports a possible pathogenic
role. There are many plausible scenarios by which TNF
may interfere with CD8  T cell responses (refer to Intro-
duction). The effects of TNF on CD8  T cells might be di-
rect (e.g., via modulation of the thresholds of T cell activa-
Figure 6. MK2 and JNK2 kinase signals associate with the modulation
of intestinal mononuclear apoptosis in the context of TNF-mediated
IBD. (A) Quantitation of the infiltrating and apoptotic cells and the per-
centage of apoptotic cells in the infiltrate (apoptotic index) in the lamina
propria of signaling-deficient Tnf ARE/  mice. *, values of statistical signif-
icance relative to the Tnf ARE/  group. Representative photomicrographs
of paraffin-embedded ileal sections from (B) Tnf ARE/  mice bred into (C)
MK2- or (D) Jnk2-deficient backgrounds followed by the in situ detec-
tion of apoptotic cells. Alkaline phosphatase–labeled apoptotic cells were
visualized using Fast Blue substrate and counterstaining with Nuclear Fast
Red. B–D,  300.1572 Molecular and Cellular Pathways in TNF-mediated IBD
tion or their rate of apoptosis) although evidence for such a
mechanism is currently lacking. Alternatively, TNF may af-
fect the nature of the innate signals that influence the char-
acter of the CD8  response (40). The observation that ef-
fector TNF signaling on bone marrow–derived cells is fully
sufficient to drive the development of pathology supports
the hemopoietic origin of TNF targets in IBD. An addi-
tional interesting observation in this study is that deficiency
in the CD4  T cell compartment exacerbates IBD in Tnf-
 ARE  mice, suggesting that CD4   T cells may regulate
pathogenic CD8  T cell responses in this model. Recently,
it was demonstrated that CD4  CD25  were capable of
suppressing CD8  activation in vitro (41). Therefore, it is
possible that such a form of modulation also exists in the
Tnf ARE mice, although the efficiency and specificity of this
interaction remain to be determined.
Our evidence indicates that TNF-dependent mecha-
nisms driving the aberrant and pathogenic CD8  T cell re-
sponses may not only be initiated by TNF targeting di-
rectly bone marrow–derived cell targets, but that also tissue
stromal cells may constitute independent direct TNF tar-
gets with equal pathogenic capacity. TNF can induce a
multiplicity of responses in stromal cells. For example, in-
testinal epithelial cells readily apoptose after the administra-
tion of TNF in vivo (13). In addition, TNF can increase
the ability of epithelial and endothelial cells to secrete po-
tent chemotactic cytokines, such as IL-8 and monocyte
chemoattractant protein-1, which serve to increase the
movement of macrophages and granulocytes from the cir-
culation into the inflamed mucosa (42), supporting chronic
intestinal inflammation. Finally, TNF can increase the pres-
ence of MHC class II antigen-presenting molecules on the
surfaces of epithelial cells and endothelial cells thus increas-
ing their ability to present lumenal antigens and bacterial
products (43). This could result in the loss of mucosal toler-
ance to innocuous antigens or autoantigens (44) or even in
the assault of the mucosal barrier and its attack by an acti-
vated lymphocytic response (45).
Signaling Requirements in TNF-driven IBD. The ab-
sence of the ARE from the Tnf gene in the Tnf ARE mice
provided us with the opportunity to examine the involve-
ment of specific effector signals delivered by TNF in IBD
in the absence of a parallel impact of such signals on TNF
biosynthesis itself. We have previously shown that produc-
tion of TNF from a Tnf ARE allele cannot be modulated by
SAP kinase blockade (5, 7), nor by the genetic ablation of
the Tpl2 kinase (19). In this study, analysis of the impact of
genetic ablation of MK2, JNK2, or Tpl2 kinases in the IBD
pathology developing in the Tnf ARE mice led to differen-
tial results on the development of intestinal inflammation.
In the absence of p38/MK2 signaling, TNF-dependent
IBD is exacerbated. In general, the p38/MK2 signaling
pathway is considered to be proinflammatory due to its po-
tentiating effects on proinflammatory cytokine biosynthesis
(17). Surprisingly, therefore, the effector role of this kinase
in IBD is shown here to be antiinflammatory. The follow-
ing evidence are in support of an effect of the p38 pathway
on lymphocyte modulation and thus to the cellular cascades
supporting IBD in Tnf ARE mice: (a) continuous MKK6/
p38 signaling in lymphocytes has been shown to result in
the selective killing of CD8  peripheral lymphocytes (46),
(b) genetic deficiency in the p38 activating kinases MKK3
or MKK6 blocks peripheral or thymic T lymphocyte apop-
tosis, respectively (47), and (c) inactivation of p38 by so-
dium salicylate blocks the antiapoptotic transcription factor,
nuclear factor (NF) B (48). In this study, disease exacerba-
tion in the absence of MK2 correlated with decreased
apoptosis in the LPMC fraction of the mucosa, indicating
that regulation of LPMC survival might be an important
mechanism of MK2 function in disease.
Development of IBD in the absence of JNK2 was signif-
icantly attenuated. In JNK2-deficient mice, stimulated
lymphocytes hypoproliferate, produce less IL-2 and IFN ,
and are unable to establish a Th-1 response (18, 34). In ad-
dition, they are unable to mount correct innate responses
to viral infections (49). Although not directly assessed in
our system, it is plausible that incorrect innate activation
and lack of a Th-1 response suppresses TNF-induced intes-
tinal inflammation. Previous reports have failed to assign a
role for this kinase in the modulation of peripheral T cell
apoptosis (18, 34). We observed that in the absence of
JNK2, the rate of LPMC apoptosis is increased, indicating
that in the context of TNF-induced inflammation this ki-
nase may promote antiapoptotic signals in the periphery.
Despite the wealth of information on the potential roles of
MAPK/SAPK signaling in inflammation, the immune effec-
tor functions of the Tpl2 kinase have not been previously
addressed. In terms of the adaptive immune response, Tpl2
may directly modulate the pathogenic lymphocytic response
because its absence from Tnf ARE/  mice correlates with a re-
duction of activated/memory CD4  and CD8  peripheral T
cells (Fig. 5). The activation of Tpl2 has been associated with
the proliferative control of lymphocytes (50). In addition,
peripheral T lymphocytes from Tpl2-deficient animals un-
dergo rapid apoptosis in the presence of antigenic stimula-
tion and IL-2 (unpublished data). On the other hand, Tpl2
can modulate the production of key innate effectors like
COX-2 (51). Tpl2 has been demonstrated to activate a
pleiotropy of downstream signals in vitro including MAPKs/
SAPKs, NF B, and caspase-mediated signals (52–54), al-
though in vivo evidence for these responses is currently lack-
ing. Recently, Tpl2 has been detected to interact with TNF
receptor–associated factor 2 to promote the activation of
NF B (55), indicating that Tpl2 might be directly impli-
cated into the diverse array of responses instigated by the
TNF receptor superfamily. It is conceivable, therefore, that
Tpl2 may affect both innate and adaptive immune responses
to support the development of intestinal inflammation.
Concluding Remarks. The data presented in this report
suggest that, in cellular terms, a critical element in TNF-
induced Crohn’s-like IBD is the activation of a Th1-driven
pathogenic CD8  T cell response. This sensitizing effect of
TNF on the adaptive immune response appears to be trans-
duced by multiple and redundant signals that target bone
marrow–derived and/or tissue stroma cells to finally con-
verge in the critical production of IL-12 and IFN-  and in1573 Kontoyiannis et al.
the activation of the deleterious CD8  T cell response. In
molecular terms, genetic inactivation experiments revealed
that at least two kinases, Tpl2 and JNK2, promote, whereas
a third one, MK2, opposes the induction of IBD, indicat-
ing that regardless of pleiotropy of cellular processes that
these signals modulate, they are likely candidates for phar-
maceutical targeting. Although these kinases may directly
transduce TNF receptor–instigated signals, the specific cell
type(s) and the critical pathway(s) with which they interfere
to modulate development of IBD remains to be elucidated.
Our data provide new mechanistic insights into the patho-
physiology of IBD and identify Tpl2 and JNK2 kinases as
potential targets for therapy.
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